Spinal Muscular Atrophy Type 3 Clinical Trial
Official title:
A Multi-center, Open Label, Single-arm, Dose Ascending Clinical Trial for Evaluation of Safety and Efficacy of Gene Therapy Drug GC101 in the Treatment of Spinal Muscular Atrophy (SMA) Type 3 Patients
The study will evaluate safety and efficacy of intrathecal delivery of GC101 gene therapy drug as a treatment of spinal muscular atrophy Type 3 (SMA 3) patients.
The purpose of this trial is to evaluate safety and efficacy of gene therapy drug GC101 in SMA 3 patients. Open-label, dose-escalation clinical trials of GC101 will be conducted in multiple centers in China. GC101 will be administrated intrathecally. Short-term safety will be evaluated in 52 weeks and enter long-term follow-up study of 5 years at will. Patients will be tested at baseline and followed up at various time points. The primary analysis for efficacy will be assessed at 12 months after treatment with GC101 on the changes from baseline HFMSE (Hammersmith Functional Motor Scale Expanded) and RULM(Revised Upper Limb Module) scores for patients of age ≥ 6 years old. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06300996 -
Spinal Cord Stimulation for the Treatment of Motor Deficits in People With Spinal Muscular Atrophy - Upper Limb
|
N/A | |
Completed |
NCT04193085 -
Wearable Technology to Assess Gait Function in SMA and DMD
|
||
Completed |
NCT02895789 -
Oxidative Capacity and Exercise Tolerance in Ambulatory SMA
|
||
Terminated |
NCT03819660 -
Long Term Safety of Amifampridine Phosphate in Spinal Muscular Atrophy 3
|
Phase 2 | |
Recruiting |
NCT05272969 -
Pompe & Pain - Study to Assess Nociceptive Pain in Adult Patients With Pompe Disease
|
||
Recruiting |
NCT05544994 -
The Effect of Aerobic Exercise Training in Patients With Type III Spinal Muscular Atrophy
|
N/A | |
Completed |
NCT02227823 -
Safety and Efficacy Study of Pyridostigmine on Patients With Spinal Muscular Atrophy Type 3
|
Phase 2 | |
Active, not recruiting |
NCT05156320 -
Efficacy and Safety of Apitegromab in Patients With Later-Onset Spinal Muscular Atrophy Treated With Nusinersen or Risdiplam
|
Phase 3 | |
Recruiting |
NCT03709784 -
Spinraza in Adult Spinal Muscular Atrophy
|
||
Terminated |
NCT03056144 -
Whole Body Vibration Therapy in Children With Spinal Muscular Atrophy
|
N/A | |
Active, not recruiting |
NCT05430113 -
Spinal Cord Stimulation in Spinal Muscular Atrophy
|
N/A | |
Completed |
NCT03921528 -
An Active Treatment Study of SRK-015 in Patients With Type 2 or Type 3 Spinal Muscular Atrophy
|
Phase 2 | |
Active, not recruiting |
NCT05626855 -
Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of Apitegromab-ONYX
|
Phase 3 | |
Completed |
NCT04907162 -
Musculoskeletal Nociceptive Pain in Participants With Neuromuscular Disorders
|